The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
GSK invests 300 million in bispecific antibody for potential lupus treatment
GSK is set to pay $300 million to license a bispecific antibody from Chimagen Biosciences, aimed at treating autoimmune diseases like lupus. Currently in Phase 1 testing for cancer, the drug targets B cells by engaging T cells, potentially offering a novel therapeutic option for B cell-driven conditions. GSK plans to initiate its own Phase 1 trial next year, pending regulatory approval.
GSK RSV vaccine shows effectiveness over three seasons but wanes over time
GSK's RSV vaccine, Arexvy, demonstrated 63% overall efficacy and 67% against severe disease over three seasons, though effectiveness declined to 48% in the third season. The CDC currently does not recommend a second dose, but GSK anticipates that revaccination may be necessary to maintain protection. The findings will be presented at the CHEST 2024 Annual Meeting.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.